Residency · Dallas, TX
Sponsored by University of Texas Southwestern Medical Center
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.
Circulation · 2023 · 1,349 citations · Ann Marie Navar
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Journal of the American College of Cardiology · 2026 · 144 citations · Ann Marie Navar
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Circulation · 2026 · 103 citations · Ann Marie Navar
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.
Journal of the American College of Cardiology · 2023 · 484 citations · Ann Marie Navar
Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.
JAMA · 2025 · 117 citations · Ann Marie Navar
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
JAMA · 2026 · 49 citations · Ann Marie Navar
Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a).
The New England journal of medicine · 2025 · 113 citations · Ann Marie Navar
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
The New England journal of medicine · 2025 · 88 citations · Ann Marie Navar